clinical trial · NCT02183168
Evaluation of Efficacy and Safety of Meloxicam Suppository (15mg Daily) and Tablet (15 mg Daily) Compared to Indomethacin Suppository (50 mg Daily) in Patients With Ankylosing Spondylitis
Boehringer Ingelheim·phase3·completed·n = 192
Spondylitis, AnkylosingMeloxicam suppositoryMeloxicam tabletIndomethacin
brief summary
Study to assess the efficacy and safety of meloxicam suppository 15 mg once daily, meloxicam tablet 15 mg once daily compared with Indomethacin suppository (50 mg daily) in patients with ankylosing spondylitis
started
Jul 1, 2001
primary completion
May 1, 2002
completion
—
last updated
Nov 24, 2023
official title
A Randomized, Open Label, 3-arm Evaluation of Efficacy and Safety of Meloxicam Suppository (15mg Daily) and Tablet (15 mg Daily) Compared to Indomethacin Suppository (50 mg Daily) in Patients With Ankylosing Spondylitis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol